Business & Regulation

What can we expect the US life sciences sector to look like over the course of the next four years as Donald Trump takes up his presidency?

Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

What lies ahead for the future of pharma? Dennis van Rooji gives his view.

Trump withdraws the US from the WHO and pharma stakeholders call for changes to price negotiation program

AI helps make preclinical decisions faster, but stakeholders remain cautious. We asked an expert from Elsevier for their views on the challenges.

AI is not just for the drug development phase of pharmaceutical manufacturing. Now is the time for the business side to leverage it.

New medicines save lives, but they take too long to get to market. Could AI make a difference?

Personalized medicine, digital therapeutics, and GLP-1s; experts tell us what areas are hot in pharma’s future.